EP1404680A2 - Process for preparing intermediates of hiv protease inhibitors - Google Patents

Process for preparing intermediates of hiv protease inhibitors

Info

Publication number
EP1404680A2
EP1404680A2 EP01271082A EP01271082A EP1404680A2 EP 1404680 A2 EP1404680 A2 EP 1404680A2 EP 01271082 A EP01271082 A EP 01271082A EP 01271082 A EP01271082 A EP 01271082A EP 1404680 A2 EP1404680 A2 EP 1404680A2
Authority
EP
European Patent Office
Prior art keywords
furan
propynyloxy
group
ealkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01271082A
Other languages
German (de)
French (fr)
Inventor
Roman Glaxosmithkline Davis
Thomas Claiborne GlaxoSmithKline LOVELACE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP1404680A2 publication Critical patent/EP1404680A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Definitions

  • HIV human immunodeficiency virus
  • AIDS acquired immunodeficiency syndrome
  • ARC AIDS-related complex
  • drugs currently used to treat HIV infections in humans are those that inhibit the HIV aspartyl protease enzyme.
  • Drugs that are used as protease inhibitors are, in general, chemically complex and are difficult to prepare in a cost-effective and efficient manner. As a 15 result of the inherent complexity of these molecules, new and more efficient methods for their preparation are of value.
  • a key step in the preparation of the hexahydrofuro[2,3-b]furan ring system is the cyclization of a 2-(2-propynyloxy)tetrahydrofuranyl derivative under radical cyclization conditions.
  • Ghosh et. al. reported that 3-iodo-2-(2- propynyloxy)tetrahydrofuran could be cyclized to the desired 3-methylene hexahydrofuro[2,3-6jfuran derivative using stoichiometric amounts of compounds capable of
  • radical initiators such as a mixture of sodium borohydride and cobaloxime.
  • the same cyclization reaction can be effected using a stoichiometric amount of a trialkyltin hydride, such as tributyltin hydride.
  • a trialkyltin hydride such as tributyltin hydride.
  • toxicity of trace amounts of metals such as cobalt or tin.
  • we developed a new process for the preparation of the hexahydrofuro[2,3-6]furan ring system that avoids the use of toxic metals in the key cyclization step.
  • radical cyclization of 0-allylic-2-halo sugar derivatives to afford alpha-C(2)-branched sugars has been described by Mesmaeker, et. al. (Synlett 1990, p. 201). This method utilizes radical initiating compounds, such as a combination of AIBN and tributyltin hydride, in addition to the use of light to effect the desired cyclizations.
  • the invention comprises a method for effecting intramolecular cyclization reactions using light, in the absence of radical initiators, to provide useful polycyclic compounds.
  • the present invention further provides a method of preparation of an intermediate useful in the synthesis of compounds that function as inhibitors of the aspartyl protease enzyme of human immunodeficiency virus (HIV).
  • the present method is characterized by the use of light to effect cyclization of a hexahydrofuro[2,3-6]furan ring system from a 2-(2- propynyloxy)tetrahydrofuranyl derivative without the use of a stoichiometric amount of a radical initiator.
  • hexahydrofuro[2,3-fa]furan derivative may be transformed through a series of further reactions to produce hexahydrofuro[2,3-b]furan-3-ol, an intermediate in the synthesis of compounds that are effective as inhibitors of HIV aspartyl protease.
  • the present method involves the use of light to effect the intramolecular cyclization of an appropriately substituted organic halo compound containing a pendant olefinic or alkynyl substituent
  • A which may be the same or different, is independently selected from the group consisting of -CH 2 - ( -CHR 10 -, -CR 10 R 11 -, -0-, -NH-, -NR 10 -, -S-; wherein R 10 and R 11 , which may be the same or different, are selected from the group consisting of hydrogen, Ce-uaryl, and G-ealkyl;
  • R 1 is selected from the group consisting of hydrogen, Ci-ealkyl, Ce- ⁇ aryl, Ci-ealkylheterocycle, and heterocycle;
  • R 2 is selected from the group consisting of hydrogen, Ce-uaryl, Ci- ⁇ alkyl, Ce-waryl, G-ealkylheterocycIe, and hetero
  • the present invention features a process for the preparation of a compound having the formula
  • A which may be the same or different, is independently selected from the group consisting of -CH2-, -CHR 10 -, -CR 10 R 11 -, -0-, -NH-, -NR 10 -, and -S-, wherein R 10 and R 11 , which may be the same or different, are selected from the group consisting of hydrogen, Ce-uaryl, and Ci-ealkyl; R 1 is selected from the group consisting of hydrogen, Ci-ealkyl, Ce-uaryl, Ci- ealkylheterocycle, and heterocycle;
  • R 4 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci- ealkylheterocycle, and heterocycle
  • R 5 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, G- ealkylheterocycle, heterocycle, -OR 12 , and -CH2OR 12 , wherein R 12 is selected from the group consisting of Ci-ealkyl and -C(0)R 10 ;
  • R 1 to R 6 are as hereinbefore defined to light with a wavelength of 200 to 400 nanometers in the presence of a compound of formula NR 7 R 8 R 9 , wherein R 7 , R 8 and R 9 , are independently selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, Ci-ealkylheterocycle, and heterocycle.
  • the present invention further features a process for the preparation of 3- methyIenehexahydrofuro[2,3-b]furan in the absence of radical initiators comprising exposing a 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to light with a wavelength from 200 to 400 nanometers, in the presence of a solvent containing a compound of formula NR 7 R 8 R 9 , wherein R 7 , R 8 and R 9 , are independently selected from the group consisting of hydrogen, Ce- uaryl, Ci-ealkyl, Ci-ealkylheterocycle, and heterocycle, thereby cyclizing the 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative to form 3-methylenehexahydrofuro[2,3-o]furan.
  • the present invention also features a process for the preparation of hexahydrofuro[2,3- 6]furan-3-ol consisting of: a) exposing a 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to light with a wavelength from 200-400 nanometers in the presence of a solvent containing a compound of formula NR 7 R 8 R 9 , wherein R 7 , R 8 and R 9 , are independently selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci-ealkylheterocycle, and heterocycle, thereby cyclizing the 3-ha!o-2-(2-propynyloxy)tetrahydrofuranyi derivative to form 3- methylenehexahydrofuro[2,3-b]furan; b) oxidizing said 3-methylenehexahydrofuro[2,3-rj]furan to produce tetrahydrofuro[2,3- ⁇ ]furan-3(2
  • the present invention includes a process as described above wherein the 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative may be 3-iodo-2-(2-propynyloxy)tetrahydrofuran, 3-bromo-2-(2-propynyloxy)tetrahydrofuran, or 3-chloro-2-(2-propynyloxy)tetrahydrofuran, the light is at a wavelength of 254 nanometers, and the compound of formula NR 7 R 8 R 9 is triethylamine.
  • the processes of the present invention involve the initial preparation of a suitable substrate for the intramolecular photocyclization reaction. These substrates can be prepared by a number of methods known to one skilled in the art.
  • preparation of a 3- halo-2-(2-propynyloxy)tetrahydrofuranyl derivative is effected by reaction of 2,3- dihydrofuran with 2-propyn-1-ol in the presence of a suitable activating agent, to provide a 3-halo-2-(2-propynyloxy)tetrahydrofuran derivative.
  • 3-halo-2-(2- propynyloxy)tetrahydrofuran derivatives can be 3-iodo-2-(2-propynyloxy)tetrahydrofuran, 3- bromo-2-(2-propynyloxy)tetrahydrofuran or 3-chloro-2-(2-propynyloxy)tetrahydrofuran.
  • This reaction can be effected using an agent capable of activating the 2,3-dihydrofuran ring to nucleophilic addition by the alcoholic portion of a 2-propyn-1-ol derivative.
  • an agent capable of activating the 2,3-dihydrofuran ring to nucleophilic addition by the alcoholic portion of a 2-propyn-1-ol derivative can be performed using N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS), in a non-nucleophilic solvent, such as dichloromethane, and at temperatures from -10 °C to 25 °C, preferably 0 °C, followed by warming to 25 °C.
  • the 3-halo-2-(2-propynyloxy)tetrahydrofuran derivative such as 3-iodo-2-(2- propyny!oxy)tetrahydrofuran, 3-bromo-2-(2-propyny!oxy)tetrahydrofuran or 3-chloro-2-(2- propynyloxy)tetrahydrofuran, may be cyclized using light, in the presence of a trialkyl amine and in the presence of a suitable solvent. This reaction may be performed using a light source that is sufficient to cause homolytic cleavage of the carbon-halogen bond in the 3 ⁇ halo-2-(2- propynyloxy)tetrahydrofuran derivative.
  • the light source used can provide ultraviolet light of sufficient intensity to cause the desired homolytic cleavage of the carbon- halogen bond.
  • a light source is used that provides light with a wavelength of 254 nanometers, produced by low-pressure mercury lamps.
  • These reactions may be performed in a suitable solvent, one that is sufficiently stable under the photolytic conditions.
  • the reaction may be performed in a polar solvent such as acetonitrile.
  • the cyclization reaction may be performed in the presence of a suitable trialkylamine of formula NR 7 R 8 R 9 , wherein R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, Ci-ealkyl, Ce-uaryl, heterocycle, and Ci-ealkylheterocycle, preferably Ci-ealkyl.
  • R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, Ci-ealkyl, Ce-uaryl, heterocycle, and Ci-ealkylheterocycle, preferably Ci-ealkyl.
  • the amine is triethylamine.
  • the reaction may be advantageously performed in the presence of water. The amount of water that may be used will vary depending on both the solvent and the trialkylamine chosen.
  • the reaction may be performed in any suitable reaction vessel that will allow the passage of a sufficient amount of light in the preferred wavelength.
  • the reaction may be advantageously performed in a vessel that is suitable as a flow-cell reactor.
  • the 3-bromo-2-(2-propynyloxy)tetrahydrofuran may be photolyzed using light at a wavelength of 254 nanometers, in a 3:7:5 ratio of acetonitrile, triethylamine and water at 20 °C for 15-20 hours, to afford 3-methylenehexahydrofuro[2,3-6]furan (Scheme IV).
  • the intermediate meth ⁇ lenehexahydrofuro[2,3-b]furan may then be oxidized to produce the desired tetrahydrofuro[2,3-b]furan-3(2f/)-one.
  • the oxidation may be performed using a variety of methods well known to those skilled in the art.
  • the olefin can be allowed to react with osmium (IV) oxide, followed by treatment with an agent capable of cleaving the resulting diol, sodium periodate for example.
  • the olefin can be treated with ozone in a suitable solvent, followed by the addition of an agent capable of cleaving the resulting ozonide.
  • the intermediate tetrahydrofuro[2,3-b]furan-3(2 /)-one may then be reduced to yield hexahydrofuro[2,3-b]furan-3-ol.
  • the reduction may be performed using an appropriate reducing agent, sodium borohyride or diisobutylaluminum hydride, or more preferably lithium aluminum hydride, in the presence of an aprotic, organic solvent, preferably dichloromethane, and at a temperature from 0 °C to 40 °C, preferably in the range from 20-30 °C.
  • an appropriate reducing agent will depend on factors known to those skilled in the art and include the properties of the particular compound being reduced and those of the solvent in which the reaction is being performed.
  • tetrahydrofuro[2,3-b]furan-3(2/V)-one may be allowed to react with lithium aluminum hydride in dichloromethane as solvent and at a temperature range of 20-30 °C to yield hexahydrofuro[2,3-b]furan-3-ol as a racemic mixture(Scheme VI).
  • Enantioenriched hexahydrofuro[2,3-b]furan-3-ol may also be obtained by the use of so- called “chiral reducing agents.” These agents are capable of reducing ketones and aldehydes in an enantioselective fashion to provide enantioenriched alcohols. The reactions may be performed with stoichiometric as well as catalytic chiral reducing agents using conditions known to those skilled in the art. For example, see Ernest L Eliel, "Stereochemistry of Organic Compounds," John Wiley & Sons, Inc., 1994, p. 941.
  • a racemic mixture of hexahydrofuro[2,3-b]furan-3-ol may be resolved to provide an enantioenriched mixture of each enantiomer.
  • a racemic mixture of hexahydrofuro[2,3-b]furan-3-ol may be resolved by converting the mixture of enantiomers into a mixture of diastereomers, followed by traditional methods of separation, such as silica chromatography.
  • the racemic alcohol may be allowed to react with a chiral nonracemic compound (the resolving agent) resulting in the formation of a diastereomeric mixture.
  • the chiral nonracemic compound is either an acid chloride or a chloroformate, resulting in the formation of a diastereomeric mixture of esters or ureas, respectively.
  • the choice of the chiral nonracemic resolving agent will depend on factors known to those skilled in the art. For example, see Eliel, et. al., p. 322.
  • the racemic alcohol may be allowed to react with a lipase enzyme capable of converting one enantiomer of the alcohol into an ester.
  • the ester and the remaining alcohol may then be separated by methods known to those skilled in the art. See Eliel, et. al., p. 413.
  • racemic alcohol may be separated into two enantioenriched mixtures by the use of an esterase.
  • These reactions typically consist of first converting the racemic alcohol to an appropriate ester, such as the corresponding acetate.
  • the conversion of the alcohol to the corresponding ester can be accomplished by reaction of the alcohol with an appropriate agent, an acid chloride or anhydride for example.
  • These reactions are typically performed in an aprotic solvent, tetrah ⁇ drofuran for example, and in the presence of a compound capable of acting as a base, sodium carbonate for example.
  • a compound capable of acting as a catalyst may be advantageously used, for example 4-N,N-dimethylaminopyridine.
  • the racemic mixture of esters may then be allowed to react with an appropriate esterase enzyme under conditions which allow for reaction of predominantly one racemate of the ester to provide a mixture of an alcohol of predominantly one enantiomer and the remaining ester, consisting of predominantly the other enantiomer.
  • the mixture of alcohol and ester may then be separated using methods known to those skilled in the art, silica gel chromatography for example.
  • the choice of an appropriate esterase enzyme, as well as appropriate reaction conditions will depend on a number of factors known to those skilled in the art. Eliel, et. al., p. 409.
  • racemic hexahydrofuro[2,3-b]furan-3-ol may be allowed to react with acetic anhydride in a mixture of tetrahydrofuran and water, and in the presence of sodium carbonate and 4-N,N-dimethylaminopyridine to yield hexahydrofuro[2,3- b]furan-3-y! acetate.
  • the resulting acetate may then be allowed to react with PS-800 in a buffered mixture of sodium hydrogen phosphate while the pH is kept between 6.2 and 7.2 with the addition of 15% aqueous sodium hydroxide as needed to yield a mixture of (3/?,3a5,6a/?)-hexahydrofuro[2,3-b]furan-3-yl acetate and (3S,3a/?,6aS)-hexahydrofuro[2,3- b]furan-3-ol (Scheme VII).
  • alkyl refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms.
  • alkyl radicals include, but are not limited to, methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like.
  • aryl refers to a carbocyclic aromatic radical (such as phenyl or naphthyl) containing the specified number of carbon atoms, preferably from 6-14 carbon atoms, and more preferably from 6-10 carbon atoms.
  • aryl radicals include, but are not limited to phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl, anthracenyl and the like.
  • aryl ring may be optionally substituted with one or more groups independently selected from the group consisting of halogen, Ci-ealkyl, -CF 3 , heterocycle, -OCH 3 , aryl, G-ealkylaryl, and G-ealkylheterocycle.
  • halogen refers to a radical of chlorine, bromine or iodine.
  • heterocycle refers to a 3-to 7- membered monocydic heterocyclic ring or 8-to 11- membered bicyclic heterocyclic ring which is either saturated, partially saturated or unsaturated, and which may be optionally benzofused if monocydic.
  • Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of N, 0 and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any carbon or heteroatom, which results in the creation of a stable structure.
  • Preferred heterocycles include 5-7 membered monocydic heterocycles and 8-10 membered bicyclic heterocycles. Examples of such groups include imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoqinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl,
  • a vessel suitable for use as a flow-cell reactor for photolytic chemical reactions comprises a hollow container with a smooth, reflective interior, constructed of a suitable material, preferably stainless steel, an inlet and outlet suitable for the introduction and removal of a chemical reaction mixture, and a light source capable of providing light in the range of 200-400 nanometers, preferably 254 nanometers.
  • N-bromosuccinimide N-bromosuccinimide (NBS, 1.05 eq., 2.67 wt), followed by methylene chloride (10 vol).
  • NBS N-bromosuccinimide
  • methylene chloride 10 vol
  • the resulting slurry was cooled to 0 °C, and a mixture of 2,3- dihydrofuran (1 eq., 1.0 wt), and propargyl alcohol (1.5 eq., 1.2 wt) was added over 40 min.
  • the resulting clear solution was stirred at 0 °C for 1 h, heated to 25 °C over 30 min and held at that temperature overnight.
  • the solution was then washed with water (1 x 10 vol), 25% sodium meta-bisulfite (2 x 5 vol) and saturated sodium bicarbonate (2 5 vol).
  • Detector type and temperature FID, 300 °C;
  • Temperature ramp 20 degrees/min to 250 °C, followed by a 7.5 min hold.
  • a reactor was charged with 3-methylenehexahydrofuro[2,3-b]furan (1 eq., 1.0 wt), and methylene chloride (10 vol). The solution was stirred and cooled to - 30 °C. Ozone was introduced through a subsurface addition line while the temperature was kept at -30 +/- 5 °C. When the solution turned blue, it was purged with nitrogen and triethylamine (2.0 eq) was slowly added, keeping the temperature between -30 and -20 °C. After the addition was complete, the solution was allowed to warm to 20 °C and was allowed to stir overnight.
  • Carrier gas He @ 1 mL/min
  • Inject 1 uL sample prep The sample concentration may be adjusted as needed to give adequate sensitivity or to prevent column overloading.
  • Carrier gas He at 5 mL/min; Makeup gas: He at 25 mL/min;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The invention describes a method for effecting intramolecular cyclization reactions using light, in the absence of radical initiators, to provide useful polycyclic compounds.

Description

Process for Preparing Intermediates of HIV Protease Inhibitors
Background of the Invention 5
The human immunodeficiency virus ("HIV") is the causative agent for acquired immunodeficiency syndrome ("AIDS"), a disease characterized by the destruction of the immune system, particularly of CD4+ T-cells, with attendant susceptibility to opportunistic infections, and its precursor AIDS-related complex ("ARC"), a syndrome characterized by 10 symptoms such as persistent generalized lymphadenopathy, fever and weight loss.
Among the drugs currently used to treat HIV infections in humans are those that inhibit the HIV aspartyl protease enzyme. Drugs that are used as protease inhibitors are, in general, chemically complex and are difficult to prepare in a cost-effective and efficient manner. As a 15 result of the inherent complexity of these molecules, new and more efficient methods for their preparation are of value.
The synthesis of hexahydrofuro[2,3-6]furan-3-ol, an intermediate in the synthesis of HIV aspartyl protease inhibitors, was described by Ghosh, et. al. (_/. Med. Chem. 1996, 39(17), p.
20 3278). A key step in the preparation of the hexahydrofuro[2,3-b]furan ring system is the cyclization of a 2-(2-propynyloxy)tetrahydrofuranyl derivative under radical cyclization conditions. For example, Ghosh et. al. reported that 3-iodo-2-(2- propynyloxy)tetrahydrofuran could be cyclized to the desired 3-methylene hexahydrofuro[2,3-6jfuran derivative using stoichiometric amounts of compounds capable of
25 acting as radical initiators, such as a mixture of sodium borohydride and cobaloxime.
Alternatively, the same cyclization reaction can be effected using a stoichiometric amount of a trialkyltin hydride, such as tributyltin hydride. There are disadvantages to such methods for the synthesis of pharmaceutical intermediates, for example, toxicity of trace amounts of metals such as cobalt or tin. As a result of toxicity concerns, we developed a new process for the preparation of the hexahydrofuro[2,3-6]furan ring system that avoids the use of toxic metals in the key cyclization step.
The cyclization of O-alkenyl aryl radicals to provide dihydrobenzofurans has been described by Beckwith, et. al. (J. Chem. Soc, Chem. Comm. 1981, p. 136). In these reactions, 2- halo-O-allylic phenolic precursor was prepared and the required aryl radical intermediate was generated using tributyltin hydride.
The radical cyclization of 0-allylic-2-halo sugar derivatives to afford alpha-C(2)-branched sugars has been described by Mesmaeker, et. al. (Synlett 1990, p. 201). This method utilizes radical initiating compounds, such as a combination of AIBN and tributyltin hydride, in addition to the use of light to effect the desired cyclizations.
Summary of the Invention
The invention comprises a method for effecting intramolecular cyclization reactions using light, in the absence of radical initiators, to provide useful polycyclic compounds. The present invention further provides a method of preparation of an intermediate useful in the synthesis of compounds that function as inhibitors of the aspartyl protease enzyme of human immunodeficiency virus (HIV). The present method is characterized by the use of light to effect cyclization of a hexahydrofuro[2,3-6]furan ring system from a 2-(2- propynyloxy)tetrahydrofuranyl derivative without the use of a stoichiometric amount of a radical initiator. The hexahydrofuro[2,3-fa]furan derivative may be transformed through a series of further reactions to produce hexahydrofuro[2,3-b]furan-3-ol, an intermediate in the synthesis of compounds that are effective as inhibitors of HIV aspartyl protease.
Detailed Description of the Invention
The present method involves the use of light to effect the intramolecular cyclization of an appropriately substituted organic halo compound containing a pendant olefinic or alkynyl substituent The invention is summarized in Schemes I, II, and IV wherein A, which may be the same or different, is independently selected from the group consisting of -CH2-( -CHR10-, -CR10R11-, -0-, -NH-, -NR10-, -S-; wherein R10 and R11, which may be the same or different, are selected from the group consisting of hydrogen, Ce-uaryl, and G-ealkyl; R1 is selected from the group consisting of hydrogen, Ci-ealkyl, Ce-πaryl, Ci-ealkylheterocycle, and heterocycle; R2 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-εalkyl, Ce-waryl, G-ealkylheterocycIe, and heterocycle; R3 is selected from the group consisting of hydrogen, Ce- uaryl, Ci-βalkyl, Cι-6alkyIheterocycle, and heterocycle; R4 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci-ealkylheterocycle, and heterocycle; R5 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci-ealkylheterocycle, heterocycle, -OR12, and -CH2OR12, wherein R12 is selected from the group consisting of Ci-ealkyl and -C(0)R10; R6 is selected from the group consisting of hydrogen, Ce-ι aryi, Ci-ealkyl, Ci-ealkylheterocycle, heterocycle, -OR12, and -CH2OR12, wherein R12 is selected from the group consisting of Ci-ealkyl and -C(0)R10; R7, R8 and R9, which may be the same or different are selected from the group consisting of hydrogen, Gs-uaryl, Ci-ealkyl, Ci-ealkylheterocycle, and heterocycle; X is halogen; and n = 1-4.
Scheme
light Scheme II
light The present invention features a process for the preparation of a compound having the formula
wherein,
A, which may be the same or different, is independently selected from the group consisting of -CH2-, -CHR10-, -CR10R11-, -0-, -NH-, -NR10-, and -S-, wherein R10 and R11, which may be the same or different, are selected from the group consisting of hydrogen, Ce-uaryl, and Ci-ealkyl; R1 is selected from the group consisting of hydrogen, Ci-ealkyl, Ce-uaryl, Ci- ealkylheterocycle, and heterocycle;
R4 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci- ealkylheterocycle, and heterocycle; R5 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, G- ealkylheterocycle, heterocycle, -OR12, and -CH2OR12, wherein R12 is selected from the group consisting of Ci-ealkyl and -C(0)R10 ;
R6 is selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci- ealkylheterocycle, heterocycle, -OR12, and -CH2OR12; and n = 1 -4 said process comprising: exposing a compound having the formula
wherein R1 to R6 are as hereinbefore defined to light with a wavelength of 200 to 400 nanometers in the presence of a compound of formula NR7R8R9, wherein R7, R8 and R9, are independently selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, Ci-ealkylheterocycle, and heterocycle.
The present invention further features a process for the preparation of 3- methyIenehexahydrofuro[2,3-b]furan in the absence of radical initiators comprising exposing a 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to light with a wavelength from 200 to 400 nanometers, in the presence of a solvent containing a compound of formula NR7 R8 R9, wherein R7, R8 and R9, are independently selected from the group consisting of hydrogen, Ce- uaryl, Ci-ealkyl, Ci-ealkylheterocycle, and heterocycle, thereby cyclizing the 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative to form 3-methylenehexahydrofuro[2,3-o]furan.
The present invention also features a process for the preparation of hexahydrofuro[2,3- 6]furan-3-ol consisting of: a) exposing a 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to light with a wavelength from 200-400 nanometers in the presence of a solvent containing a compound of formula NR7 R8 R9, wherein R7, R8 and R9, are independently selected from the group consisting of hydrogen, Ce-uaryl, Ci-ealkyl, Ci-ealkylheterocycle, and heterocycle, thereby cyclizing the 3-ha!o-2-(2-propynyloxy)tetrahydrofuranyi derivative to form 3- methylenehexahydrofuro[2,3-b]furan; b) oxidizing said 3-methylenehexahydrofuro[2,3-rj]furan to produce tetrahydrofuro[2,3- σ]furan-3(2 /)-one; and c) reducing said tetrahydrofuro[2,3-o]furan-3(2ft)-one to yield hexahydrofuro[2,3-σ]furan- 3-ol.
The present invention includes a process as described above wherein the 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative may be 3-iodo-2-(2-propynyloxy)tetrahydrofuran, 3-bromo-2-(2-propynyloxy)tetrahydrofuran, or 3-chloro-2-(2-propynyloxy)tetrahydrofuran, the light is at a wavelength of 254 nanometers, and the compound of formula NR7 R8 R9 is triethylamine. The processes of the present invention involve the initial preparation of a suitable substrate for the intramolecular photocyclization reaction. These substrates can be prepared by a number of methods known to one skilled in the art. For example, preparation of a 3- halo-2-(2-propynyloxy)tetrahydrofuranyl derivative is effected by reaction of 2,3- dihydrofuran with 2-propyn-1-ol in the presence of a suitable activating agent, to provide a 3-halo-2-(2-propynyloxy)tetrahydrofuran derivative. For example, such 3-halo-2-(2- propynyloxy)tetrahydrofuran derivatives can be 3-iodo-2-(2-propynyloxy)tetrahydrofuran, 3- bromo-2-(2-propynyloxy)tetrahydrofuran or 3-chloro-2-(2-propynyloxy)tetrahydrofuran. This reaction can be effected using an agent capable of activating the 2,3-dihydrofuran ring to nucleophilic addition by the alcoholic portion of a 2-propyn-1-ol derivative. For example, the reaction can be performed using N-bromosuccinimide (NBS) or N-iodosuccinimide (NIS), in a non-nucleophilic solvent, such as dichloromethane, and at temperatures from -10 °C to 25 °C, preferably 0 °C, followed by warming to 25 °C. For example, 2,3-dihydrofuran was allowed to react with 2-propyn-1-ol in dichloromethane and in the presence of NBS to provide 3-bromo-2-(2-propynγloxγ)tetrahydrofuran (Scheme III).
Scheme
.0.
The 3-halo-2-(2-propynyloxy)tetrahydrofuran derivative, such as 3-iodo-2-(2- propyny!oxy)tetrahydrofuran, 3-bromo-2-(2-propyny!oxy)tetrahydrofuran or 3-chloro-2-(2- propynyloxy)tetrahydrofuran, may be cyclized using light, in the presence of a trialkyl amine and in the presence of a suitable solvent. This reaction may be performed using a light source that is sufficient to cause homolytic cleavage of the carbon-halogen bond in the 3~halo-2-(2- propynyloxy)tetrahydrofuran derivative. For example, the light source used can provide ultraviolet light of sufficient intensity to cause the desired homolytic cleavage of the carbon- halogen bond. Preferably, a light source is used that provides light with a wavelength of 254 nanometers, produced by low-pressure mercury lamps. These reactions may be performed in a suitable solvent, one that is sufficiently stable under the photolytic conditions. For example, the reaction may be performed in a polar solvent such as acetonitrile. It has also been found that the cyclization reaction may be performed in the presence of a suitable trialkylamine of formula NR7R8R9, wherein R7, R8, and R9 are independently selected from the group consisting of hydrogen, Ci-ealkyl, Ce-uaryl, heterocycle, and Ci-ealkylheterocycle, preferably Ci-ealkyl. Preferably the amine is triethylamine. We have discovered that the reaction may be advantageously performed in the presence of water. The amount of water that may be used will vary depending on both the solvent and the trialkylamine chosen.
The reaction may be performed in any suitable reaction vessel that will allow the passage of a sufficient amount of light in the preferred wavelength. The reaction may be advantageously performed in a vessel that is suitable as a flow-cell reactor.
For example, the 3-bromo-2-(2-propynyloxy)tetrahydrofuran may be photolyzed using light at a wavelength of 254 nanometers, in a 3:7:5 ratio of acetonitrile, triethylamine and water at 20 °C for 15-20 hours, to afford 3-methylenehexahydrofuro[2,3-6]furan (Scheme IV).
Scheme IV
The intermediate methγlenehexahydrofuro[2,3-b]furan may then be oxidized to produce the desired tetrahydrofuro[2,3-b]furan-3(2f/)-one. The oxidation may be performed using a variety of methods well known to those skilled in the art. For example, the olefin can be allowed to react with osmium (IV) oxide, followed by treatment with an agent capable of cleaving the resulting diol, sodium periodate for example. Alternatively, the olefin can be treated with ozone in a suitable solvent, followed by the addition of an agent capable of cleaving the resulting ozonide. These reactions are typically performed in an organic solvent that is stable to the reaction conditions, dichloromethane for example, and at temperatures from -75 °C to 25 °C, advantageously from -30 ° to 20 °C. For example, methylenehexahydrofuro[2,3-b]furan may be allowed to react with ozone in methylene chloride at -30 °C, followed by warming to -20 °C and the addition of triethylamine, to provide tetrahydrofuro[2,3-b]furan-3(2 V)-one (Scheme V). Scheme V
The intermediate tetrahydrofuro[2,3-b]furan-3(2 /)-one may then be reduced to yield hexahydrofuro[2,3-b]furan-3-ol. The reduction may be performed using an appropriate reducing agent, sodium borohyride or diisobutylaluminum hydride, or more preferably lithium aluminum hydride, in the presence of an aprotic, organic solvent, preferably dichloromethane, and at a temperature from 0 °C to 40 °C, preferably in the range from 20-30 °C. The choice of an appropriate reducing agent will depend on factors known to those skilled in the art and include the properties of the particular compound being reduced and those of the solvent in which the reaction is being performed. For example, tetrahydrofuro[2,3-b]furan-3(2/V)-one may be allowed to react with lithium aluminum hydride in dichloromethane as solvent and at a temperature range of 20-30 °C to yield hexahydrofuro[2,3-b]furan-3-ol as a racemic mixture(Scheme VI).
Scheme VI
1. LiAIH4, DCM
Enantioenriched hexahydrofuro[2,3-b]furan-3-ol may also be obtained by the use of so- called "chiral reducing agents." These agents are capable of reducing ketones and aldehydes in an enantioselective fashion to provide enantioenriched alcohols. The reactions may be performed with stoichiometric as well as catalytic chiral reducing agents using conditions known to those skilled in the art. For example, see Ernest L Eliel, "Stereochemistry of Organic Compounds," John Wiley & Sons, Inc., 1994, p. 941.
Alternatively, a racemic mixture of hexahydrofuro[2,3-b]furan-3-ol may be resolved to provide an enantioenriched mixture of each enantiomer. There are several different methods to accomplish this type of resolution known to those skilled in the art.
First, a racemic mixture of hexahydrofuro[2,3-b]furan-3-ol may be resolved by converting the mixture of enantiomers into a mixture of diastereomers, followed by traditional methods of separation, such as silica chromatography. In this type of resolution, the racemic alcohol may be allowed to react with a chiral nonracemic compound (the resolving agent) resulting in the formation of a diastereomeric mixture. Typically, the chiral nonracemic compound is either an acid chloride or a chloroformate, resulting in the formation of a diastereomeric mixture of esters or ureas, respectively. The choice of the chiral nonracemic resolving agent will depend on factors known to those skilled in the art. For example, see Eliel, et. al., p. 322.
Next, the racemic alcohol may be allowed to react with a lipase enzyme capable of converting one enantiomer of the alcohol into an ester. The ester and the remaining alcohol may then be separated by methods known to those skilled in the art. See Eliel, et. al., p. 413.
Lastly, the racemic alcohol may be separated into two enantioenriched mixtures by the use of an esterase. These reactions typically consist of first converting the racemic alcohol to an appropriate ester, such as the corresponding acetate. The conversion of the alcohol to the corresponding ester can be accomplished by reaction of the alcohol with an appropriate agent, an acid chloride or anhydride for example. These reactions are typically performed in an aprotic solvent, tetrahγdrofuran for example, and in the presence of a compound capable of acting as a base, sodium carbonate for example. In addition, a compound capable of acting as a catalyst may be advantageously used, for example 4-N,N-dimethylaminopyridine. The racemic mixture of esters may then be allowed to react with an appropriate esterase enzyme under conditions which allow for reaction of predominantly one racemate of the ester to provide a mixture of an alcohol of predominantly one enantiomer and the remaining ester, consisting of predominantly the other enantiomer. The mixture of alcohol and ester may then be separated using methods known to those skilled in the art, silica gel chromatography for example. The choice of an appropriate esterase enzyme, as well as appropriate reaction conditions will depend on a number of factors known to those skilled in the art. Eliel, et. al., p. 409. For example, racemic hexahydrofuro[2,3-b]furan-3-ol may be allowed to react with acetic anhydride in a mixture of tetrahydrofuran and water, and in the presence of sodium carbonate and 4-N,N-dimethylaminopyridine to yield hexahydrofuro[2,3- b]furan-3-y! acetate. The resulting acetate may then be allowed to react with PS-800 in a buffered mixture of sodium hydrogen phosphate while the pH is kept between 6.2 and 7.2 with the addition of 15% aqueous sodium hydroxide as needed to yield a mixture of (3/?,3a5,6a/?)-hexahydrofuro[2,3-b]furan-3-yl acetate and (3S,3a/?,6aS)-hexahydrofuro[2,3- b]furan-3-ol (Scheme VII).
Scheme VII
The term "alkyl", alone or in combination with any other term, refers to a straight-chain or branched-chain saturated aliphatic hydrocarbon radical containing the specified number of carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, n-hexyl and the like. The term "aryl," alone or in combination with any other term, refers to a carbocyclic aromatic radical (such as phenyl or naphthyl) containing the specified number of carbon atoms, preferably from 6-14 carbon atoms, and more preferably from 6-10 carbon atoms. Examples of aryl radicals include, but are not limited to phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl, anthracenyl and the like. In addition, the aryl ring may be optionally substituted with one or more groups independently selected from the group consisting of halogen, Ci-ealkyl, -CF3, heterocycle, -OCH3, aryl, G-ealkylaryl, and G-ealkylheterocycle.
The term "halogen" refers to a radical of chlorine, bromine or iodine.
The term "heterocycle" or "heterocyclic" as used herein, refers to a 3-to 7- membered monocydic heterocyclic ring or 8-to 11- membered bicyclic heterocyclic ring which is either saturated, partially saturated or unsaturated, and which may be optionally benzofused if monocydic. Each heterocycle consists of one or more carbon atoms and from one to four heteroatoms selected from the group consisting of N, 0 and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any carbon or heteroatom, which results in the creation of a stable structure. Preferred heterocycles include 5-7 membered monocydic heterocycles and 8-10 membered bicyclic heterocycles. Examples of such groups include imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoqinolyl, indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl, pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl, pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl, carbolinyl, tetrazolyl, thiazolidinyl, benzofuranoyl, thiamorpholinyl sulfone, oxazolyl, benzoxazolyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl, azepinyl, isoxozolyl, isothiazolyl, furazanyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolyl, thiadiazoyl, dioxolyl, dioxinyl, oxathiolyl, benzodioxolyl, dithiolyl, thiophenyl, tetrahydrothiophenyl, sulfolanyl, dioxanyl, dioxolanyl, tetahydrofurodihydrofuranyl, tetrahydropyranodihydrofuranyl, dihydropyranyl, tetradγrofurofuranyl and tetrahydropyranofuranyl. The term "flow-cell reactor" refers to a vessel that is suitable for use in chemical reactions. In general, a vessel suitable for use as a flow-cell reactor for photolytic chemical reactions comprises a hollow container with a smooth, reflective interior, constructed of a suitable material, preferably stainless steel, an inlet and outlet suitable for the introduction and removal of a chemical reaction mixture, and a light source capable of providing light in the range of 200-400 nanometers, preferably 254 nanometers.
The following examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
Example 1
A. 3-Bromo-2-(2-propynyloxy)tetrahydrofuran.
A reactor was charged with N-bromosuccinimide (NBS, 1.05 eq., 2.67 wt), followed by methylene chloride (10 vol). The resulting slurry was cooled to 0 °C, and a mixture of 2,3- dihydrofuran (1 eq., 1.0 wt), and propargyl alcohol (1.5 eq., 1.2 wt) was added over 40 min. The resulting clear solution was stirred at 0 °C for 1 h, heated to 25 °C over 30 min and held at that temperature overnight. The solution was then washed with water (1 x 10 vol), 25% sodium meta-bisulfite (2 x 5 vol) and saturated sodium bicarbonate (2 5 vol). The resulting solution was then concentrated under vacuum to an oil. Acetonitrile (1 vol) was added, and the solution concentrated to an oil under vacuum to provide 3-bromo-2-(2- propynyloxy)tetrahydrofuran. 1H NMR of the title compound was identical to that found in the literature (Ghosh, et. al., J. Med. Chem. 1996, 39(17), p. 3278).
B. 3~Methylenehexahydrofuro[2,3-b]furan 3-bromo-2-(2-propynyloxy)tetrahydrofuran (1 eq., 1 wt) was dissolved in acetonitrile (3 vol), triethylamine (10.3 eq., 7 vol) and water (5 vol) in a jacketed reactor. The solution was stirred at 20 °C and was circulated through a stainless photoreactor equipped with ten 13.8W low-pressure, mercury lamps (254 nm output) for 15-20h. After the appropriate reaction time, the mixture was concentrated to an oil. 1H NMR of the title compound was identical to that found in the literature (Ghosh, et. al., 1 Meet Chem. 1996, 39(17), p. 3278). Reaction progress was followed using a gas chromatograph under the following conditions: Column: DB-62430 m x 0.53 mm column with a 3 micron film thickness; Carrier gas: He at 5 mL/min; Injector temperature: 250 °C;
Detector type and temperature: FID, 300 °C;
Initial oven temperature: 100 °C;
Temperature ramp: 20 degrees/min to 250 °C, followed by a 7.5 min hold.
Retention time of 3-methylenehexahydrofuro[2,3-b]furan = 4.9 min.
C. Tetrahydrofuro[2,3-b]furan-3(2r/)-one
A reactor was charged with 3-methylenehexahydrofuro[2,3-b]furan (1 eq., 1.0 wt), and methylene chloride (10 vol). The solution was stirred and cooled to - 30 °C. Ozone was introduced through a subsurface addition line while the temperature was kept at -30 +/- 5 °C. When the solution turned blue, it was purged with nitrogen and triethylamine (2.0 eq) was slowly added, keeping the temperature between -30 and -20 °C. After the addition was complete, the solution was allowed to warm to 20 °C and was allowed to stir overnight. After stirring overnight, 3 N HCI and 5% brine solution (3.2 vol) were added at such a rate as to keep the temperature of the reaction mixture below 30 °C. The layers were then separated and the organic layer was washed with 5°/o brine solution, and then concentrated under vacuum (15 mbar) to provide tetrahydrofuro[2,3-b]furan-3(2/V)-one as an oil. 1H NMR of the title compound was identical to that found in the literature (Ghosh, et. al., J. Med. Chem. 1996, 39(17), p. 3278).
P. Hexahydrofuro[2,3-b]furan-3-ol
A reactor was charged with tetrahydrofuro[2,3-b]furan-3(2 /)-one (1.0 eq., 1.0 wt) and methylene chloride (5 vol). Lithium aluminum hydride (1 M in tetrahydrofuran, 0.45 eq., 5.9 vol) was added slowly in order to keep the reaction temperature below 30 °C. After the addition was complete, the reaction was stirred an additional 30 min and then was cooled in an ice bath. The following were successively added at a rate such that the temperature of the reaction mixture remained below 20 °C: 25% water in THF (4 vol v. LAH solid wt), 15% w/v sodium hydroxide (3 vols v. LAH solid wt), and water (1 vol v. LAH solid wt). Celite was added immediately after the addition of water was complete and the resulting slurry was stirred for 1h. The slurry was then filtered through a coarse fritted funnel, and the filter cake was washed with THF (2 vol). The filtrate and washings were combined and were used in the next step without further purification or manipulation. 1H NMR of the title compound was identical to that found in the literature (Ghosh, et al., J. Med. Chem. 1996, 39(17), p. 3278).
E. Hexahydrofuro[2,3-b]furan-3-yl acetate A reactor was charged with sodium carbonate (2.5 eq., 2.0 wt) the filtrate from step D above, and 4,4-N,N-dimethylaminopyridine (0.05 eq., 0.04 wt). The resulting mixture was cooled in an ice bath and acetic anhydride (1.5 eq., 1.1 vol) was added at such a rate that the reaction mixture stayed below 10 °C. The mixture was then allowed to warm to room temperature and stir overnight. The resulting slurry was filtered through a coarse fritted funnel and the filter cake was washed with methylene chloride (2 vol). The filtrate and washings were combined and were further extracted with 1 N HCI (1 vol). The mixture was then concentrated under vacuum to provide hexahydrofuro[2,3-b]furan-3-yl acetate as an oil. 'H NMR of the title compound was identical to that found in the literature (Ghosh, et. al., J. Med. Chem. 1996, 39(17), p. 3278).
F. (3ff,3aS,6afi)-Hexahydrofuro[2,3-b]furan-3-yl acetate
A reactor was charged with 0.1 N NaHP0 (pH = 7.0, 7.5 vol) and hexahydrofuro[2,3- b]furan-3-yl acetate (1eq., 1 wt). The pH of the solution was then adjusted to 7.0 by the addition of 15% sodium hydroxide and the solution was heated to 35 +/- 3 °C. PS-800 (500 units/mmol) was then added and the pH was kept between 6.8 and 7.2 with the periodic addition of 15% sodium hydroxide. Reaction progress was followed by chiral gas chromatography until all of the undesired acetate had been hydrolyzed. Celite (0.5 wt) was then added, followed by methylene chloride (4.0 vol), and the resulting slurry was stirred for 15 min. The mixture was then filtered through a pad of celite, followed by several washes of the celite pad with methylene chloride. The organic layer was separated and the organic layer was washed with water (3 x 1 vol), 10% sodium chloride (2 vol) and then was concentrated under vacuum to provide (3/?,3aS,6a/?)-hexahydrofuro[2,3-b]furan-3-yl acetate as an oil. 'H
NMR of the title compound was identical to that found in the literature (Ghosh, et. al., J. Med.
Chem. 1996, 39(17), p. 3278). Typical optical purity of the resulting (3/?,3aS,6afl)- hexahydrofuro[2,3-b]furan-3-yl acetate was >98% ee. Optical purity was determined using chiral GC under the following conditions:
Column: Astec Chiraldex Beta Cyclodextrin Trifluoroacetyl (B-TA) 20 m X 0.25 mm;
Carrier gas: He @ 1 mL/min;
Make-up gas: He @ 30 mL/min Detection: FID @ 300°C
Injection: : 1uL @ 250°C (split)
Split flow: 100 mL/min
Total run time: 30 min
Temperature program: Isothermal @ 115°C Sample preparation: Approximately 25 - 50 mg sample (1 -2 drops) in 10 mL acetonitrile .
Inject 1 uL sample prep. The sample concentration may be adjusted as needed to give adequate sensitivity or to prevent column overloading.
Retention times: (3S,3a/?,6aS)-Hexahydrofuro[2,3-b]furan-3-yl acetate = 1 1.43 min; (3/?,3aS,6a/?)-Hexahydrofuro[2,3-b]furan-3-yl acetate = 12.20 min.
G. (3 ?,3aS,6a ?)-hexahydrofuro[2,3-b3furan-3-ol
A reactor was charged with (3/?,3a5,6a/?)-Hexahydrofuro[2,3-b]furan-3-yl acetate (1 eq., 1 wt), methanol (3 vol) and potassium carbonate (0.001 eq, 0.001 wt). The mixture was allowed to stir at rt for 18-20 h, after which time the reaction mixture was concentrated to afford (3 ?,3aS6aR)-hexahydrofuro[2,3-b]furan-3-oI as an oil. 'H NMR of the title compound was identical to that found in the literature (Ghosh, et al., J. Med. Chem. 1996, 39(17), p. 3278).
Reaction progress was followed using gas chromatography under the following conditions:
Column: DB-624, 30 m x 0.53 mm x 3 micron film thickness;
Carrier gas: He at 5 mL/min; Makeup gas: He at 25 mL/min;
Detector: FID at 300 °C; Initial oven temperature: 100 °C for 0 min;
Temperature ramp: 20 °C/min, to 250 °C, followed by a 7.5 min hold.
Retention time of (3/?,3a5,6aft)-hexahydrofuro[2,3-b]furan-3-ol = 6.55 min.

Claims

We Claim:
1. A process for the preparation of a compound having the formula
wherein,
A, which may be the same or different, is independently selected from the group consisting of -CH2-, -CHR10-, -CR10R11-, -0-, -NH-, -NR10-, and -S-, wherein R10 and R11, which may be the same or different, are selected from the group consisting of hydrogen, Ce-uaryl, and G-ealkyl;
R1 is selected from the group consisting of hydrogen, G-ealkyl, Ce-uaryl, Ci- ealkylheterocycle, and heterocycle;
R4 is selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, Ci- ealkylheterocycle, and heterocycle; Rs is selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, Ci- ealkylheterocycle, heterocycle, -OR12, and -CH2OR12, wherein R12 is selected from the group consisting of G-ealkyl and -C(0)R10 ;
R6 is selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, Ci- ealkylheterocycle, heterocycle, -OR12, and -CH2OR12; and n = 1-4 said process comprising: exposing a compound having the formula
wherein R1 - R6 are as hereinbefore defined, to light with a wavelength of 200 to 400 nanometers in the presence of a compound of formula NR7R8R9, wherein R7, R8 and R9, are independently selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, G-ealkylheterocycle, and heterocycle.
2. A process for the preparation of 3-methylenehexahydrofuro[2,3-b]furan in the absence of radical initiators comprising exposing a 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to light with a wavelength from 200 to 400 nanometers, in the presence of a solvent containing a compound of formula NR7 R8 R9, wherein R7, R8 and R9, are independently selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, G- ealkylheterocycle, and heterocycle, thereby cyclizing the 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative to form 3-methylenehexahydrofuro[2,3-b]furan.
3. A process for the preparation of hexahydrofuro[2,3-b]furan-3-ol consisting of: a) exposing a 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to light with a wavelength from 200-400 nanometers in the presence of a solvent containing a compound of formula NR7 R8 R9, wherein R7, R8 and R9, are independently selected from the group consisting of hydrogen, Ce-uaryl, G-ealkyl, G-6alkylheterocycle, and heterocycle, thereby cyclizing the 3-halo-2-(2-propynyloxy)tetrahydrofuranyl derivative to form 3- methylenehexahydrofuro[2,3-b]furan; b) oxidizing said 3-methylenehexahydrofuro[2,3-b]furan to produce tetrahydrofuro[2,3- b]furan-3(2 /)-one; and c) reducing said tetrahydrofuro[2,3-b]furan-3(2/7)-one to yield hexahydrofuro[2,3- b]furan-3-ol.
4. A process according to claim 2 or 3, wherein the 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative is selected from the group consisting of 3-iodo- 2-(2-propynyloxy)tetrahydrofuran, 3-bromo-2-(2-propynyloxy)tetrahydrofuran, and 3- chloro-2-(2-propynyloxy)tetrahydrofuran.
5. A process according to any of claims 1 - 3 wherein said light is ultraviolet light.
6. A process according to any of claims 1 - 3 wherein said light is at a wavelength of 254 nanometers.
7. A process according to any of claims 1 - 3 wherein said compound of formula NR7 R8 R9 is triethylamine.
8. A process according to claim 2 or 3 wherein said solvent contains water.
9. A process according to claims 2 or 3 wherein said 3-halo-2-(2- propynyloxy)tetrahydrofuranyl derivative is selected from the group consisting of 3-iodo- 2-(2-propynyloxy)tetrahydrofuran, 3-bromo-2-(2-propynyloxy)tetrahydrofuran, and 3- chloro-2-(2-propynyloxy)tetrahydrofuran; said light is at a wavelength of 254 nanometers; and said compound of formula NR7 R8 R9 is triethylamine.
10. A process according to any of claims 1 - 3 wherein the process is performed in an apparatus suitable for use as a flow-cell reactor.
EP01271082A 2000-10-24 2001-10-22 Process for preparing intermediates of hiv protease inhibitors Withdrawn EP1404680A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24282200P 2000-10-24 2000-10-24
US242822P 2000-10-24
PCT/US2001/051428 WO2002067239A2 (en) 2000-10-24 2001-10-22 Process for preparing intermediates of hiv protease inhibitors

Publications (1)

Publication Number Publication Date
EP1404680A2 true EP1404680A2 (en) 2004-04-07

Family

ID=22916319

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01271082A Withdrawn EP1404680A2 (en) 2000-10-24 2001-10-22 Process for preparing intermediates of hiv protease inhibitors

Country Status (4)

Country Link
EP (1) EP1404680A2 (en)
JP (1) JP2004519473A (en)
AU (1) AU2002255473A1 (en)
WO (2) WO2002060905A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340788T1 (en) * 2002-06-27 2006-10-15 Smithkline Beecham Corp PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA)HEXAHYDROFURO(2,3-BÖFURAN-3-OL
SI1999133T1 (en) * 2006-03-29 2013-10-30 Gilead Sciences, Inc. Process for preparation of hiv protease inhibitors
PL2089371T3 (en) 2006-11-09 2011-06-30 Janssen Sciences Ireland Uc Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol
CN103864813B (en) * 2012-12-18 2017-02-22 上海迪赛诺化学制药有限公司 Synthetic methods of hexahydrofuro[2,3-b]furan-3-ol and enantiomer thereof
CN107607635B (en) * 2017-08-15 2020-07-31 东北制药集团股份有限公司 Method for detecting content of propiolic alcohol in levophosphamide salt by adopting headspace gas chromatography
AR120680A1 (en) 2019-12-06 2022-03-09 Vertex Pharma SUBSTITUTED TETRAHYDROFURANES AS SODIUM CHANNEL MODULATORS
AR126073A1 (en) 2021-06-04 2023-09-06 Vertex Pharma N-(HYDROXYALKYL(HETERO)ARYL)TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02067239A3 *

Also Published As

Publication number Publication date
AU2002255473A1 (en) 2002-09-04
WO2002067239A3 (en) 2004-01-08
JP2004519473A (en) 2004-07-02
WO2002067239A2 (en) 2002-08-29
WO2002060905A2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
JP6889232B2 (en) Large cyclization reactions and intermediates useful in the synthesis of halichondrin B analogs
Ihara et al. Asymmetric total synthesis of atisine via intramolecular double Michael reaction
Martin et al. Application of nitrile oxide cycloadditions to a convergent, asymmetric synthesis of (+)-phyllanthocin
Zubkov et al. Skeletal Wagner–Meerwein rearrangement of perhydro-3a, 6; 4, 5-diepoxyisoindoles
Yeoman et al. A unified strategy for the synthesis of (−)-maoecrystal Z,(−)-trichorabdal A, and (−)-longikaurin E
CN109641917A (en) It can be used for synthesizing the prins reaction and intermediate of halichondrins macrolides and the like
Majumdar et al. Synthesis of five-and six-membered heterocyclic compounds by the application of the metathesis reactions
EP1404680A2 (en) Process for preparing intermediates of hiv protease inhibitors
Finch et al. Synthesis of the spiroacetal core of the cephalosporolide family of natural products
Bergmeier et al. Aziridine− Allylsilane-Mediated Total Synthesis of (−)-Yohimbane
Xu et al. Synthesis of the polyketide segment of apratoxin A
KR900005624B1 (en) Intermediates for the production of epipodophyllotoxin and related compounds and process for the preparation thereof
Gomez et al. Serial radical cyclization of pyranose-derived dienes in the stereocontrolled synthesis of Woodward's reserpine precursor
US7145024B2 (en) Process for preparing protease inhibitor intermediates
Wang et al. Cocatalyst-controlled divergent cascade cycloaddition reaction of arylalkynols and dioxopyrrolidienes: access to spiroketals and oxa-bridged eight-membered cyclic ethers
US20040026230A1 (en) Process for preparing intermediates of hiv protease inhibitors
Palange et al. TiCl 4-n-Bu 3 N-mediated cascade annulation of ketones with α-ketoesters: a facile synthesis of highly substituted fused γ-alkylidene-butenolides
Maezaki et al. 1, 5-Benzodithiepan-3-one 1, 5-dioxide: A novel chiral auxiliary for asymmetric desymmetrization of meso-1, 2-diols
Tanaka et al. Ruthenium-Catalyzed Asymmetric Dehydrative Allylic Cyclization of Five-Membered Chalcogen Heteroaromatics
AU2002352205A1 (en) Preparation of cis-fused 3,3a,8,12b-tetrahydro-2H-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives
Brimble et al. Enantioselective synthesis of an analogue of nanaomycin A
B Luesse et al. Synthesis of a functionalized oxabicyclo [2.2. 1]-heptene-based chemical library
Cecchet et al. Synthesis and Diels-Alder reactions of enantiopure (−)-trans-benzo [d]-dithiine-S, S'-dioxide
Sauret et al. Chiral 2-and 8-functionalised 1, 7-dioxaspiro [5.5] undecanes via asymmetric dihydroxylation
Xie et al. Preparation of Two Diastereoisomeric Decalin Synthons and (−)‐Ambrox

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20050119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050531